On April 8, 2016, the FDA updated labeling recommendations for metformin and metformin-containing drugs, expanding the indication(s) to include treatment for type 2 diabetes patients with mild-to-moderate renal impairment. This should cause metformin to be more widely prescribed, which may help nearly half of type 2 diabetes sufferers with renal impairment or chronic kidney disease (CKD). This development also provides updated guidelines for assessing kidney function, directing physicians to use the more robust eGFR test in place of a simple serum creatinine test.

Click here to read the release from the FDA.